Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
ObjectiveThe purpose of this study was to estimate the cost-effectiveness of sugemalimab plus chemotherapy (SC) vs. placebo plus chemotherapy (PC), as the first-line treatment for patients with non-small cell lung cancer (NSCLC) in China.Material and methodsA three-state Markov model with a cycle of...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | 图书 |
| 出版: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
| 主题: | |
| 在线阅读: | Connect to this object online. |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
因特网
Connect to this object online.3rd Floor Main Library
| 索引号: |
A1234.567 |
|---|---|
| 复印件 1 | 可用 |